General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Immuneering in Series B Financing

January 6, 2021
The US$62 million financing was led by a Boston-based emerging companies team.

Immuneering Corporation has announced the completion of an oversubscribed US$62 million Series B financing led by Cormorant Asset Management, with participation from Surveyor Capital (a Citadel company), Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed by BlackRock, Perceptive Advisors and LYFE Capital. Existing investors and senior management also participated in the financing.

Latham & Watkins LLP represents Immuneering Corporation in the transaction with an emerging companies deal team led by Boston partners John Chory and Evan Smith, with associates Andres Caicedo and Martha Anderson.